Latest news: in the meta-analysis of Individual Participant Data, oral dydrogesterone was associated with a significantly higher chance of ongoing pregnancy (odds ratio [OR], 1.32; 95% confidence interval [CI], 1.08 to 1.61; P = 0.0075) at 12 weeks of gestation and live birth (OR, 1.28; 95% CI, 1.04 to 1.57; P = 0.0214) compared to vaginal micronized progesterone1.
Reference: 1. Griesinger G, Blockeel C, Kahler E, et al. Dydrogesterone as an oral alternative to vaginal progesterone for IVF luteal phase support: A systematic review and individual participant data meta-analysis. PLoS ONE 15(11): e0241044.https://doi. org/10.1371/journal.pone.0241044.
This site place cookies on your machine for reasons including keeping track of your preferences, collecting aggregated statistics to analyze how our site is used, and to show you ads tailored to your interests. ACCEPT
Privacy, Cookies Policy, General Terms and Conditions of Use
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.